 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
| «12345678910111213» |
- | Inrebic (fedratinib) / BMS
Enrollment open, Metastases: A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms (clinicaltrials.gov) - Nov 22, 2021
P1, N=50, Recruiting, Sponsor: University of Chicago
Not yet recruiting --> Recruiting
- | NDI-101150 / Nimbus Therap
New P1/2 trial, Combination therapy, Monotherapy: A Study of NDI 1150-101 in Patients With Solid Tumors (clinicaltrials.gov) - Nov 21, 2021
P1/2, N=106, Recruiting, Sponsor: Nimbus Saturn, Inc.
- | Idhifa (enasidenib) / BMS, Servier
New P1 trial: A Study of Enasidenib in People With Clonal Cytopenia of Undetermined Significance (clinicaltrials.gov) - Oct 31, 2021
P1, N=15, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
- || Tibsovo (ivosidenib) / Servier
Enrollment closed, Trial completion date, Trial primary completion date, Tumor mutational burden: IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation (clinicaltrials.gov) - Oct 26, 2021
P1, N=18, Active, not recruiting, Sponsor: Massachusetts General Hospital
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial completion date: Jul 2024 --> Dec 2025 | Trial primary completion date: Jul 2021 --> Dec 2022
- ||| Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz, Idhifa (enasidenib) / BMS, Servier
Trial completion date, Trial suspension, Trial primary completion date: NCI-2018-02998: CPX-351 Plus Enasidenib for Relapsed AML (clinicaltrials.gov) - Oct 14, 2021
P2, N=18, Suspended, Sponsor: Jonsson Comprehensive Cancer Center
Recruiting --> Active, not recruiting | Trial completion date: Jul 2024 --> Dec 2025 | Trial primary completion date: Jul 2021 --> Dec 2022 Trial completion date: Jan 2022 --> Sep 2023 | Recruiting --> Suspended | Trial primary completion date: Sep 2021 --> Sep 2022
- || Idhifa (enasidenib) / BMS, Servier
Enrollment closed: P30CA016672: Azacitidine and Enasidenib in Treating Patients with IDH2-Mutant Myelodysplastic Syndrome (clinicaltrials.gov) - Oct 7, 2021
P2, N=105, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Jan 2022 --> Sep 2023 | Recruiting --> Suspended | Trial primary completion date: Sep 2021 --> Sep 2022 Recruiting --> Active, not recruiting
- ||||| Tibsovo (ivosidenib) / Servier
Trial completion, Metastases: Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy) (clinicaltrials.gov) - Oct 1, 2021
P3, N=187, Completed, Sponsor: Agios Pharmaceuticals, Inc.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||| Firsocostat (GS-0976) / Gilead, cilofexor/firsocostat (GS-9674/GS-0976) / Gilead, cilofexor (GS-9674) / Gilead
Enrollment open: Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (clinicaltrials.gov) - Sep 13, 2021
P2, N=440, Recruiting, Sponsor: Gilead Sciences
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- || Tibsovo (ivosidenib) / Servier
New P2 trial: Ivosidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH1 (clinicaltrials.gov) - Aug 31, 2021
P2, N=15, Not yet recruiting, Sponsor: Washington University School of Medicine
- | Daurismo (glasdegib) / Pfizer
Trial completion date, Trial initiation date, Trial primary completion date: Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation (clinicaltrials.gov) - Aug 18, 2021
P1b, N=36, Not yet recruiting, Sponsor: City of Hope Medical Center
Not yet recruiting --> Recruiting Trial completion date: Dec 2022 --> Dec 2023 | Initiation date: Feb 2021 --> Oct 2021 | Trial primary completion date: Dec 2022 --> Dec 2023
- | Idhifa (enasidenib) / BMS, Servier
Trial completion date, Trial primary completion date: Enasidenib as Maintenance Therapy in Treating Patients With Acute Myeloid Leukemia With IDH2 Mutation After Donor Stem Cell Transplant (clinicaltrials.gov) - Aug 18, 2021
P1, N=15, Recruiting, Sponsor: City of Hope Medical Center
Trial completion date: Dec 2022 --> Dec 2023 | Initiation date: Feb 2021 --> Oct 2021 | Trial primary completion date: Dec 2022 --> Dec 2023 Trial completion date: Dec 2020 --> Dec 2022 | Trial primary completion date: Dec 2020 --> Dec 2022
- | New P1 trial, Combination therapy: NCI-2021-08496: Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission (clinicaltrials.gov) - Aug 17, 2021
P1, N=125, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- | zasocitinib (TAK-279) / Takeda
New P2b trial: Study of NDI-034858 in Participants With Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - Aug 10, 2021
P2b, N=250, Recruiting, Sponsor: Nimbus Lakshmi, Inc.
- ||||| Firsocostat (GS-0976) / Gilead, cilofexor/firsocostat (GS-9674/GS-0976) / Gilead, cilofexor (GS-9674) / Gilead
New P2 trial: Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (clinicaltrials.gov) - Jul 20, 2021
P2, N=440, Not yet recruiting, Sponsor: Gilead Sciences
- || Tibsovo (ivosidenib) / Servier
Enrollment closed, Trial completion date: A China Bridging Study of Ivosidenib in r/r AML Subjects With an IDH1 Mutation (clinicaltrials.gov) - Jul 16, 2021
P1, N=30, Active, not recruiting, Sponsor: CStone Pharmaceuticals
Trial completion date: Dec 2020 --> Dec 2022 | Trial primary completion date: Dec 2020 --> Dec 2022 Recruiting --> Active, not recruiting | Trial completion date: May 2021 --> Oct 2022
- | Inrebic (fedratinib) / BMS
New P1 trial, Metastases: A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms (clinicaltrials.gov) - Jul 8, 2021
P1, N=50, Not yet recruiting, Sponsor: University of Chicago
- | Enrollment open, Combination therapy: NCI-2021-00893: Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Jul 5, 2021
P1b/2, N=84, Recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting | Trial completion date: May 2021 --> Oct 2022 Not yet recruiting --> Recruiting
- | Biomarker, Trial completion date, Trial primary completion date: Beat AML: Study of Biomarker-Based Treatment of Acute Myeloid Leukemia (clinicaltrials.gov) - Jun 29, 2021
P1/2, N=2000, Recruiting, Sponsor: Beat AML, LLC
Not yet recruiting --> Recruiting Trial completion date: Dec 2021 --> Dec 2023 | Trial primary completion date: Dec 2021 --> Dec 2023
- | Venclexta (venetoclax) / Roche, AbbVie, Tibsovo (ivosidenib) / Servier
Enrollment change, IO biomarker: NCI-2018-00921: Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies (clinicaltrials.gov) - Jun 28, 2021
P1/2, N=30, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Dec 2021 --> Dec 2023 | Trial primary completion date: Dec 2021 --> Dec 2023 N=48 --> 30
- |||| Tibsovo (ivosidenib) / Servier
Enrollment closed, Combination therapy: AGILE: Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation (clinicaltrials.gov) - Jun 14, 2021
P3, N=148, Active, not recruiting, Sponsor: Agios Pharmaceuticals, Inc.
N=48 --> 30 Recruiting --> Active, not recruiting
- ||| MORF-057 / Morphic Therap
Trial completion: Study of MORF 057 to Evaluate Single and Multi Ascending Doses in Healthy Volunteers (clinicaltrials.gov) - Jun 10, 2021
P1a, N=67, Completed, Sponsor: Morphic Therapeutic, Inc
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- || Tibsovo (ivosidenib) / Servier
Trial completion date, Trial primary completion date, Metastases: AG120-C-001: Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation (clinicaltrials.gov) - May 27, 2021
P1, N=291, Recruiting, Sponsor: Agios Pharmaceuticals, Inc.
Active, not recruiting --> Completed Trial completion date: Jun 2021 --> Aug 2025 | Trial primary completion date: Dec 2020 --> Feb 2025
- || Jakafi (ruxolitinib) / Incyte, Idhifa (enasidenib) / BMS, Servier
Enrollment open: MPN-RC 119: Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation (clinicaltrials.gov) - May 20, 2021
P2, N=32, Recruiting, Sponsor: John Mascarenhas
Trial completion date: Jun 2021 --> Aug 2025 | Trial primary completion date: Dec 2020 --> Feb 2025 Not yet recruiting --> Recruiting
- || Idhifa (enasidenib) / BMS, Servier
Enrollment closed, Trial primary completion date, Tumor mutational burden: IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation (clinicaltrials.gov) - May 19, 2021
P1, N=23, Active, not recruiting, Sponsor: Massachusetts General Hospital
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: May 2021 --> Jan 2022
- | Opdivo (nivolumab) / BMS, Tibsovo (ivosidenib) / Servier
Enrollment change, Trial withdrawal, Combination therapy, Checkpoint inhibition, Tumor mutational burden, Checkpoint block: A Study of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDS (clinicaltrials.gov) - May 6, 2021
P2, N=0, Withdrawn, Sponsor: Yale University
Recruiting --> Active, not recruiting | Trial primary completion date: May 2021 --> Jan 2022 N=45 --> 0 | Recruiting --> Withdrawn
- | Opdivo (nivolumab) / BMS, Tibsovo (ivosidenib) / Servier
Enrollment open, Combination therapy, Checkpoint inhibition, Tumor mutational burden, Checkpoint block: A Study of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDS (clinicaltrials.gov) - May 3, 2021
P2, N=45, Recruiting, Sponsor: Yale University
N=45 --> 0 | Recruiting --> Withdrawn Suspended --> Recruiting
- || MORF-057 / Morphic Therap
Enrollment closed: Study of MORF 057 to Evaluate Single and Multi Ascending Doses in Healthy Volunteers (clinicaltrials.gov) - Apr 28, 2021
P1a, N=67, Active, not recruiting, Sponsor: Morphic Therapeutic, Inc
Suspended --> Recruiting Recruiting --> Active, not recruiting
- | Idhifa (enasidenib) / BMS, Servier
Trial completion date, Trial primary completion date: Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation (clinicaltrials.gov) - Apr 22, 2021
P2, N=10, Recruiting, Sponsor: Children's Oncology Group
Recruiting --> Active, not recruiting Trial completion date: Dec 2021 --> Dec 2030 | Trial primary completion date: Dec 2021 --> Dec 2030
- || Opdivo (nivolumab) / BMS, Tibsovo (ivosidenib) / Servier
Enrollment open, Trial completion date, Trial primary completion date, Metastases: Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors (clinicaltrials.gov) - Apr 13, 2021
P2, N=35, Recruiting, Sponsor: Jason J. Luke, MD
Trial completion date: Dec 2021 --> Dec 2030 | Trial primary completion date: Dec 2021 --> Dec 2030 Not yet recruiting --> Recruiting | Trial completion date: Dec 2023 --> Apr 2024 | Trial primary completion date: Sep 2022 --> Dec 2022
- | Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz, Tibsovo (ivosidenib) / Servier
Enrollment open, Combination therapy: CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (clinicaltrials.gov) - Mar 29, 2021
P2, N=30, Recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting | Trial completion date: Dec 2023 --> Apr 2024 | Trial primary completion date: Sep 2022 --> Dec 2022 Not yet recruiting --> Recruiting
- | Tibsovo (ivosidenib) / Servier
Trial completion date, Trial primary completion date: IDIOME-STUDY: IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome (clinicaltrials.gov) - Mar 17, 2021
P2, N=68, Recruiting, Sponsor: Groupe Francophone des Myelodysplasies
Not yet recruiting --> Recruiting Trial completion date: Jan 2024 --> Apr 2025 | Trial primary completion date: Jan 2022 --> Apr 2025
- SDGR1 / Schrodinger
[VIRTUAL] Discovery of novel CDC7 inhibitors that disrupt cell cycle dynamics and show anti-proliferative effects in cancer cells () - Mar 11, 2021 - Abstract #AACR2021AACR_481;
We have identified novel potent ATP-competitive CDC7 inhibitors that show target engagement in cells and CDX tumors and have shown strong inhibition of cancer cell proliferation in vitro and tumor growth in vivo. CDC7 inhibitors show promise for use in combination with other targeted therapies for the treatment of cancers of varying origin.
- | Idhifa (enasidenib) / BMS, Servier
Trial completion date, Trial primary completion date: Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation (clinicaltrials.gov) - Mar 10, 2021
P2, N=10, Recruiting, Sponsor: Children's Oncology Group
CDC7 inhibitors show promise for use in combination with other targeted therapies for the treatment of cancers of varying origin. Trial completion date: Oct 2029 --> Dec 2021 | Trial primary completion date: Oct 2029 --> Dec 2021
- | Idhifa (enasidenib) / BMS, Servier
Enrollment change, Trial withdrawal: Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene Mutation (clinicaltrials.gov) - Mar 10, 2021
P2, N=0, Withdrawn, Sponsor: Roswell Park Cancer Institute
Trial completion date: Oct 2029 --> Dec 2021 | Trial primary completion date: Oct 2029 --> Dec 2021 N=86 --> 0 | Recruiting --> Withdrawn
- || Tibsovo (ivosidenib) / Servier
Trial completion date, Trial primary completion date, Metastases: Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation (clinicaltrials.gov) - Mar 9, 2021
P1, N=170, Active, not recruiting, Sponsor: Agios Pharmaceuticals, Inc.
N=86 --> 0 | Recruiting --> Withdrawn Trial completion date: Jun 2021 --> Jun 2022 | Trial primary completion date: Jun 2021 --> Jun 2022
- | Idhifa (enasidenib) / BMS, Servier
Trial completion date, Trial primary completion date: A Study of Perpetrator Drug Interactions of Enasidenib in AML Patients (clinicaltrials.gov) - Mar 9, 2021
P1, N=40, Recruiting, Sponsor: Celgene
Trial completion date: Jun 2021 --> Jun 2022 | Trial primary completion date: Jun 2021 --> Jun 2022 Trial completion date: Jul 2022 --> Oct 2022 | Trial primary completion date: Jul 2022 --> Oct 2022
- || Idhifa (enasidenib) / BMS, Servier
Enrollment open: Pharmacokinetics of Enasidenib (CC-90007) in Participants With Mild, Moderate and Severe Hepatic Impairment (clinicaltrials.gov) - Feb 21, 2021
P1, N=48, Recruiting, Sponsor: Celgene
Trial completion date: Jul 2022 --> Oct 2022 | Trial primary completion date: Jul 2022 --> Oct 2022 Not yet recruiting --> Recruiting
- | Tibsovo (ivosidenib) / Servier, Pemazyre (pemigatinib) / Incyte
Enrollment open, Metastases: Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma (clinicaltrials.gov) - Feb 5, 2021
P1, N=40, Recruiting, Sponsor: Academic and Community Cancer Research United
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Opdivo (nivolumab) / BMS, Tibsovo (ivosidenib) / Servier
Trial completion date, Trial primary completion date, Metastases: Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors (clinicaltrials.gov) - Feb 2, 2021
P2, N=35, Not yet recruiting, Sponsor: Jason J. Luke, MD
Not yet recruiting --> Recruiting Trial completion date: Oct 2022 --> Dec 2023 | Trial primary completion date: Oct 2021 --> Sep 2022
- |||| selonsertib (GS-4997) / Gilead, Firsocostat (GS-0976) / Gilead, cilofexor (GS-9674) / Gilead
Trial completion: Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH) (clinicaltrials.gov) - Jan 19, 2021
P2, N=220, Completed, Sponsor: Gilead Sciences
Trial completion date: Oct 2022 --> Dec 2023 | Trial primary completion date: Oct 2021 --> Sep 2022 Active, not recruiting --> Completed
- | Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz, Idhifa (enasidenib) / BMS, Servier
Trial primary completion date: NCI-2018-02998: CPX-351 Plus Enasidenib for Relapsed AML (clinicaltrials.gov) - Jan 19, 2021
P2, N=18, Recruiting, Sponsor: Jonsson Comprehensive Cancer Center
Active, not recruiting --> Completed Trial primary completion date: Jan 2021 --> Sep 2021
- | Tibsovo (ivosidenib) / Servier, Pemazyre (pemigatinib) / Incyte
Trial completion date, Trial primary completion date, Metastases: Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma (clinicaltrials.gov) - Dec 14, 2020
P1, N=40, Not yet recruiting, Sponsor: Academic and Community Cancer Research United
Trial primary completion date: Jan 2021 --> Sep 2021 Trial completion date: Sep 2025 --> Jan 2025 | Trial primary completion date: Nov 2021 --> Jul 2022
- || Venclexta (venetoclax) / Roche, AbbVie, Idhifa (enasidenib) / BMS, Servier
Enrollment open, Combination therapy, IO biomarker: ENAVEN-AML: Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers (clinicaltrials.gov) - Dec 9, 2020
P1/2, N=48, Recruiting, Sponsor: University Health Network, Toronto
Trial completion date: Sep 2025 --> Jan 2025 | Trial primary completion date: Nov 2021 --> Jul 2022 Not yet recruiting --> Recruiting
- | Daurismo (glasdegib) / Pfizer
New P1 trial: Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation (clinicaltrials.gov) - Dec 7, 2020
P1b, N=36, Not yet recruiting, Sponsor: City of Hope Medical Center
- | Jakafi (ruxolitinib) / Incyte, Idhifa (enasidenib) / BMS, Servier
Trial initiation date: MPN-RC 119: Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation (clinicaltrials.gov) - Dec 3, 2020
P2, N=32, Not yet recruiting, Sponsor: John Mascarenhas
Not yet recruiting --> Recruiting Initiation date: Oct 2020 --> Mar 2021
- | Idhifa (enasidenib) / BMS, Servier
Trial primary completion date: IDEAL Study: IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome (clinicaltrials.gov) - Nov 13, 2020
P2, N=68, Recruiting, Sponsor: Groupe Francophone des Myelodysplasies
Initiation date: Oct 2020 --> Mar 2021 Trial primary completion date: Feb 2021 --> Feb 2023
- ||| selonsertib (GS-4997) / Gilead, Firsocostat (GS-0976) / Gilead, cilofexor (GS-9674) / Gilead
Enrollment closed: Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH) (clinicaltrials.gov) - Oct 28, 2020
P2, N=220, Active, not recruiting, Sponsor: Gilead Sciences
Trial primary completion date: Feb 2021 --> Feb 2023 Recruiting --> Active, not recruiting
- || Tibsovo (ivosidenib) / Servier
Trial completion date, Metastases: Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy) (clinicaltrials.gov) - Oct 27, 2020
P3, N=187, Active, not recruiting, Sponsor: Agios Pharmaceuticals, Inc.
Recruiting --> Active, not recruiting Trial completion date: Aug 2020 --> Aug 2021
- | Tibsovo (ivosidenib) / Servier, Pemazyre (pemigatinib) / Incyte
Trial completion date, Metastases: Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma (clinicaltrials.gov) - Oct 7, 2020
P1, N=40, Not yet recruiting, Sponsor: Academic and Community Cancer Research United
Trial completion date: Aug 2020 --> Aug 2021 Trial completion date: Sep 2026 --> Sep 2025
- | MORF-057 / Morphic Therap
New P1 trial: Study of MORF 057 to Evaluate Single and Multi Ascending Doses in Healthy Volunteers (clinicaltrials.gov) - Oct 7, 2020
P1a, N=92, Recruiting, Sponsor: Morphic Therapeutic, Inc